NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Annovis Bio Phase 3 Alzheimer's Trial Progress and Corporate Updates FAQ
TL;DR
Annovis Bio's Phase 3 Alzheimer's trial activation and promising biomarker data position the company for a competitive advantage in the neurodegenerative disease market.
Annovis Bio activated all 84 sites in its Phase 3 Alzheimer's study and demonstrated buntanetap's mechanism through biomarker data showing reduced inflammation and neurodegeneration.
Annovis Bio's Alzheimer's treatment development offers hope for improving patient quality of life and advancing care for neurodegenerative diseases worldwide.
Annovis Bio secured patent protection through 2046 for buntanetap while reporting biomarker data showing strong reductions in inflammation and neurodegeneration.
Found this article helpful?
Share it with your network and spread the knowledge!
Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company headquartered in Malvern, Pennsylvania, dedicated to developing therapies for neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD).
The company reported full activation of all 84 sites in its pivotal Phase 3 Alzheimer's study (NCT06709014) with steady enrollment across the U.S., plus promising biomarker data from its Phase 2/3 Alzheimer's trial showing strong reductions in inflammation and neurodegeneration.
Buntanetap is Annovis Bio's investigational therapy that has demonstrated disease-modifying potential through biomarker data showing strong reductions in inflammation and neurodegeneration in Alzheimer's patients.
Recent achievements include transferring all patents to the new crystal form of buntanetap with intellectual property protection through 2046, publishing supportive pharmacokinetic data, and appointing veteran finance executive Mark Guerin as Chief Financial Officer.
According to CEO Maria Maccecchini, the company is moving toward data readouts, which represent the final step before submitting a New Drug Application (NDA) to regulatory authorities.
Maria Maccecchini, Ph.D., serves as president and CEO and stated that 'Every element is now aligned as we move toward our data readouts—the final step before an NDA submission.'
Investors can access the latest news and updates in the company's newsroom at https://ibn.fm/ANVS and follow the company on LinkedIn, YouTube, and X (formerly Twitter).
The transfer of all patents to the new crystal form of buntanetap provides intellectual property protection through 2046, securing the company's exclusive rights to this formulation for over two decades.
The pivotal Phase 3 Alzheimer's study is being conducted across 84 fully activated sites with steady enrollment occurring throughout the United States.
Curated from InvestorBrandNetwork (IBN)
